INmune Bio Plans FDA Submission for CORDStrom in Rare Skin Disease RDEB
Key Insights
INmune Bio announces plans to submit Biologics License Application (BLA) to FDA for CORDStrom (search) following successful Type C meeting.
The company will pursue marketing authorization in both US and European markets based on positive MissionEB (search) clinical trial results in pediatric RDEB (search) patients.
Double-blind, randomized, placebo-controlled MissionEB (search) study demonstrates favorable benefit-risk profile for CORDStrom (search) as a disease-modifying therapy.
INmune Bio has taken a significant step forward in its mission to treat Recessive Dystrophic Epidermolysis Bullosa (search) (RDEB (search)), announcing plans to submit regulatory applications following a productive Type C meeting with the U.S. Food and Drug Administration (FDA). The company intends to file a Biologics License Application (BLA) in the United States and corresponding Marketing Authorization Applications (MAA) in the United Kingdom and European Union.
The regulatory submissions will be supported by data from the company's MissionEB (search) clinical trial, which evaluated CORDStrom (search) as a potential disease-modifying therapy for pediatric patients suffering from RDEB (search). This rare genetic condition causes severe skin fragility and blistering, significantly impacting patients' quality of life from an early age.
Clinical Trial Results Support Regulatory Filing
The MissionEB (search) study, designed as a double-blind, randomized, placebo-controlled trial, has yielded promising results that demonstrate a favorable benefit-risk profile for CORDStrom (search). This rigorous trial design is particularly noteworthy in the context of rare disease research, where controlled studies can be challenging to conduct due to small patient populations.
Strategic Regulatory Approach
INmune Bio's decision to pursue simultaneous regulatory approvals in multiple major markets reflects a comprehensive strategy to make CORDStrom (search) available to RDEB (search) patients globally. The Type C meeting with the FDA represents a critical milestone in the development program, providing the company with regulatory clarity and confidence to proceed with submission plans.
Addressing an Unmet Medical Need
RDEB (search) represents a significant unmet medical need, with limited therapeutic options currently available for patients. CORDStrom (search)'s development as a disease-modifying therapy could potentially offer new hope to pediatric patients and their families who currently face limited treatment options for managing this devastating condition.